
Feb 4 (Reuters) - Sarepta Therapeutics Inc SRPT.O:
SAREPTA THERAPEUTICS ANNOUNCES APPROVAL OF CLINICAL TRIAL APPLICATION FOR SRP-1005, ITS INVESTIGATIONAL TREATMENT FOR HUNTINGTON’S DISEASE
SAREPTA THERAPEUTICS INC - FIRST-IN-HUMAN CLINICAL STUDY OF SRP-1005, KNOWN AS INSIGHTT, IS EXPECTED TO BEGIN IN Q2 OF 2026
SAREPTA THERAPEUTICS INC: FIRST-IN-HUMAN CLINICAL STUDY OF SRP-1005, KNOWN AS INSIGHTT, IS EXPECTED TO BEGIN IN Q2 OF 2026